

RESEARCH ARTICLE

CHRONIC NEUTROPENIA REVEALING HYPER IGM SYNDROME: A CASE REPORT

E. Bahous, R. Abilkassem, A. Radi, M. Kmari, A. Hassani and A. Agadr Pediatrics Department, Mohammed V Military Instruction Hospital, Rabat.

.....

Manuscript Info

Abstract

Manuscript History Received: 20 October 2024 Final Accepted: 23 November 2024 Published: December 2024

Key words:-

Hyper Igm Syndrome, Clinical, Neutropenia, Recurrent Infections, Therapy, Immunoglobulin Hyper IgM syndrome is a well-knownhereditaryimmunodeficiency, first describedin 1961. It iscaused by a defect in B lymphocytes, characterized by a normal or high serumlevel of IgM and a low or zerolevel of IgG, IgA, IgE resultingfrom a deficiency in isotype switching. Itsclinical manifestations are dominated by recurrent infections, especiallyrespiratory and digestive. The interest of this article is to illustrate a particular mode of revelation of hyper IgM syndromes through persistent chronicneutropenia in an infant.

Copyright, IJAR, 2024,. All rights reserved.

Introduction:-

Hyper IgM syndromes (SHIM) or Class Switch RecombinationDeficiencies (CSR-Ds) constitute a heterogeneous and rare group of immunodeficiencies, characterized by the association of a profound deficiency in IgG, IgA, and a normal or elevated level of Ig M. They are caused by a defect in isotype switching in association or not with a defect in somatichypermutation in B lymphocytes [1]. CSR-Ds are classified into 6 types, depending on the gene and the mutated protein: SHIM1 (CD40L), SHIM2 (AID), SHIM3 (CD40), SHIM5 (Ung), SHIM6 (NEMO) and SHIM7 (IKBA) [2]. In addition to recurrent infections which are the most common manifestations in the majority of cases, a number of patients sufferfrom neutropenia.

Herewe report the case of a 2-year-old childwithchronic and persistent neutropeniawhosubsequentlyrevealed a hyper-IgM syndrome.

Case report :

This was a 2-year-old boy from a non-consanguineousmarriage, wellvaccinated, with 2 healthysistersaged 10 and 17 respectively, a healthybrotheraged 19, no evidence of death in infancy and no similar cases in the family. Hispersonalhistoryincluded an anal abscess at the age of 15 months. He washospitalized at the age of 18 months for stomatitis with gingival hypertrophy, the initial assessment of which revealed profound and persistent neutropenia at 556 controlled after 15 days at 430.

Clinical exam on admission: No dysmorphic syndrome; weight= 13 kg (N), size= 95 cm (+2SD); the stomatologicalexaminationshowedsignificant gingival hypertrophy, hemorrhagic and painfulerosivegingivitisassociated with aphthae (figure 1); the pleuropulmonary and cardiovascular examination were unremarkable, no hepatosplenomegaly, no bone or joint pain, the lymphnode areas are free. The rest of the examination is normal.



Figure 1:- Gingival hypertrophy, hemorrhagic and painfulerosivegingivitisassociated with canker sores.

An initial assessmentwascarried out: Blood count: GB: 9100 including 500 PNN and 6600 Lymphocytes, Hb = 11.1g / dl, VGM = 69.2fl, TCMH = 23pg, Platelets = 402000. Liver, phosphocalcic, lipid and proteinlevels: normal. Albumin, Vitamin B12 and B9 are normal. Ferritinisalso normal. Radiologicalexaminationsincludingchest X-ray and abdominal ultrasound are withoutparticularities. The serological profile (HVB, CMV, HIV, rubella) wasnegative. A myelogramrevealed the presence of 5% blast cellswith the neutrophilicgranularlineage at 16%. A weight dosage of immunoglobulins and lymphocyte subpopulationswasdoneshowing the resultsillustrated in the following table:

Case	Igweight dosage				lymphocyte subpopulation count				
	IgM(g/l) (0,16- 1,32)	IgG(g/l) (4,42- 8,95)	IgA(g/l) (0,160- 0,980)	IgE(UI/ml) (0,1-200)	lym	CD3+	CD4+	CD8+	CD19+
August 16th	1.38	0.03	0.04		7430	74.6% 5534	66% 4904	7.2% 535	20%
August 26th	1.31	0.02	0.04	< 0,1	8180	71.4% 5841	62.3% 5096	7.6% 622	19%

The dosage of anti-vaccineantibodies revealed the absence of anti-diphtheria AC, a control of antitetanusimmunityless than 0.03 and of immunity against H. influenzae type b less than 0.1. A control of the PNN rate was carried out on this patient on a weekly then monthly basis showing the results (figure 2):



Figure 2:- Curveshowing the evolution of the PNN rate as a function of time.

The mostlikelydiagnosis in our patient ishyperimmunoglobulin M syndrome, probably type 3. The patient was put on monthly infusion of polyvalent immunoglobulins and treatmentwith cotrimoxazole, G CSF if severeneutropenia.

Discussion:-

Hyper-IgM syndromes are very rare immunodeficiencies, first describedin 1961 by Rosen et al [3]. In Morocco, theyrepresent 2.8% of primary immunodeficiencies.

The causes are molecular and can classify HIGM syndromes which are linkedeither to a signalingdefectbetween T and B lymphocytes, or to intracellular signal transmission defects induced by the interaction between CD40L and CD40. X-linked hyper IgM syndrome would represent the most frequent hyper-IgM syndromes [4] especially "in Europe where the consanguinity rate is very low. The American registry reports that the minimum incidence rate of X-HIGM wasapproximately 1 case per 1,030,000 live births [5]. AID deficiency is ranked 2nd in frequency after X-HIGM. Minegishisuge sted that 50% of non-X-linked hyper IgM syndromes were HIGM2 syndromes [6]. The other forms, autosomal recessive or dominant, are clinically heterogeneous. Several types are individualized according to the mutated gene and protein: the most frequent are SHIM1 (CD40L), SHIM2 (AID), SHIM3 (CD40), SHIM5 (UNG), SHIM6 (NEMO) and SHIM7 (IKBA).

Clinical manifestations developduring the first or second year of life for the majority of patients and are dominatedmainly by: Recurrent infections (pulmonary, ENT, digestive), Opportunistic infections, Signs of autoimmunity and Lymphoproliferation[7]. The weight dosage of immunoglobulinsis the essential element for diagnosiswith a normal or increasedlevel of IgM and a low or zerolevel of IgA, IgG, IgE. The count of lymphocyte subpopulationsis normal, we note decrease or absence of the expression of CD40 and reduction or absence of the expression of CD40L. The geneticstudyconfirms the diagnosis and specifies the type of HIGM [8].For our patient, SHIM type 3 is the mostlikelydiagnosisgiven: earlyage, healthybrother, neutropenia, recurrent infections and the absence of hypertrophy of lymphoidorgans.

Ig replacement therapyis essential to correct the clinicalconsequences of the humoral deficiencypresent in all forms of HIGM syndrome. In HIGM 2, HIGM 4 and HIGM 5 syndromes, treatmentisbasedmainly on IV Ig, which significantly reduces the incidence of bacterial infections. In HIGM1 and HIGM3 syndromes, treatment with IV Ig and TSU-based antibiotic prophylaxisis indicated in the majority of patients awaiting HSCT, thus reducing the frequency and severity of infections but does not prevently phoproliferative disease, sclerosing cholangitis and malignant diseases [9].

Conclusion:-

Neutropeniaissometimesassociated with hyperIgM syndrome, but the reasonisunclear. Prophylactic treatment with cotrimoxazole and intravenous gamma globulin prevents infections and mayalleviate neutropenia.

References:-

- 1. Tang WJ, An YF, Dai RX, Wang QH, Jiang LP, Tang XM, Yang XQ, Yu J, Tu WW, Zhao XD. Clinical, molecular, and T cellsubset analyses in a smallcohort of Chinese patients with hyper-IgM syndrome type Hum Immunol. 2014; 75(7):633-40.
- Madkaikar M, Gupta M, Chavan S, Italia K, Desai M, Merchant R, Radhakrishnan N, Ghosh K. X-linked hyper IgM syndrome: clinical, immunological and molecularfeatures in patients from India. Blood Cells Mol Dis. 2014; 53(3):99-104.
- 3. Rosen FS, Kevy SV, Merler E, Janeway CA, Gitlin D.Recurrentbacterial infections and dysgamma-globulinemia: deficiency of 7S gamma-globulins in the presence of elevated 19S gamma-globulins: report of two cases. Pediatrics. 1961; 28:182-95.
- 4. Etzioni A, Ochs HD. The hyper IgM syndrome--an evolving story. PediatrRes. 2004; 56(4):519-25.
- Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME. The X-linked hyper-IgM syndrome: clinical and immunologicfeatures of 79 patients. Medicine. 2003; 82(6):373-84.
- 6. Minegishi Y, Lavoie A, Cunningham-Rundles C, Bédard PM, Hébert J, Côté L, Dan K, Sedlak D, Buckley RH, Fischer A, Durandy A, Conley ME. Mutations in activation-inducedcytidine deaminase in patients with hyper IgM syndrome. Clin Immunol. 2000;97(3):203-10.
- Karaca NE, Forveille M, Aksu G, Durandy A, Kutukculer N. Hyper-immunoglobulin M syndrome type 3 with normal CD40 cell surface expression. Scand J Immunol. 2012; 76(1):21-5.
- Quartier P, Bustamante J, Sanal O, Plebani A, Debré M, Deville A, Litzman J, Levy J, Fermand JP, Lane P, Horneff G, Aksu G, Yalçin I, Davies G, Tezcanl, Ersoy F, Catalan N, Imai K, Fischer A, Durandy A. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol. 2004; 110(1):22-9.
- 9. Durandy A, Kracker S. The Hyper IgM Syndromes–a Long List of Genes and Years of Discovery. Elsevier AcademicPress. 2014;198-210.